STOCK TITAN

Immuron (NASDAQ: IMRN) furnishes FY25 Appendix 4E and results presentation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Immuron Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish investors with materials already released on the Australian Securities Exchange. The filing attaches two September 2, 2025 announcements: an Appendix 4E Preliminary Final Report and an FY25 results presentation. These exhibits provide the detailed financial and operational results for the fiscal year ended FY25, while the Form 6-K itself clarifies that this information is furnished to U.S. markets but is not deemed filed under the Exchange Act or automatically incorporated into other U.S. securities filings.

Positive

  • None.

Negative

  • None.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of September 2025

 

Commission File Number: 001-38104

 

IMMURON LIMITED

(Name of Registrant)

 

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ☐       No ☒

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

 

 

 

 

IMMURON LIMITED

 

EXPLANATORY NOTE

 

Immuron Limited (the “Company”) published two announcements (the “Public Notices”) to the Australian Securities Exchange on September 2, 2025 titled:

 

  - Appendix 4E Preliminary Final Report
     
  - FY25 Results Presentation

 

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

 

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

1

 

EXHIBITS

 

Exhibit
Number
  Description
99.1   Appendix 4E Preliminary Final Report
99.2   FY25 Results Presentation 

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  IMMURON LIMITED
     
Date: September 2, 2025 By:  /s/ Phillip Hains
    Phillip Hains
    Company Secretary

 

3

 

FAQ

What does Immuron Limited (IMRN) report in this Form 6-K?

Immuron Limited uses this Form 6-K to furnish two announcements previously released to the Australian Securities Exchange: an Appendix 4E Preliminary Final Report and an FY25 Results Presentation, giving U.S. investors access to its fiscal year 2025 results materials.

Which exhibits are attached to Immuron Limited’s (IMRN) September 2025 Form 6-K?

The filing attaches Exhibit 99.1, Immuron’s Appendix 4E Preliminary Final Report, and Exhibit 99.2, the FY25 Results Presentation. These exhibits contain the company’s detailed preliminary final results and related presentation for the fiscal year ended 2025.

Are Immuron’s (IMRN) FY25 results in this Form 6-K considered filed under the Exchange Act?

No, the Form 6-K states that the information, including the attached exhibits, is furnished rather than filed for purposes of the Exchange Act. It is not automatically incorporated into other U.S. securities law filings unless specifically referenced.

When were Immuron Limited’s (IMRN) FY25 announcements released on the ASX?

The company states that its two announcements, the Appendix 4E Preliminary Final Report and the FY25 Results Presentation, were published to the Australian Securities Exchange on September 2, 2025, and are now attached to this Form 6-K for U.S. markets.

Who signed Immuron Limited’s (IMRN) September 2025 Form 6-K?

The Form 6-K was signed on behalf of Immuron Limited by Company Secretary Phillip Hains. The signature section confirms he was duly authorized to sign the report dated September 2, 2025 under the Securities Exchange Act of 1934.

Does this Immuron (IMRN) Form 6-K specify financial figures for FY25?

The body of the Form 6-K itself does not list specific financial figures. Instead, it points to the attached Appendix 4E Preliminary Final Report and FY25 Results Presentation, where detailed financial and operating results for the fiscal year 2025 are provided.
Immuron Ltd

NASDAQ:IMRN

View IMRN Stock Overview

IMRN Rankings

IMRN Latest News

IMRN Latest SEC Filings

IMRN Stock Data

6.39M
8.17M
Biotechnology
Healthcare
Link
Australia
Carlton